Study of the ENTact Septal Staple System for Tissue Approximation During Septoplasty

August 20, 2009 updated by: ENTrigue Surgical, Inc.

A Prospective, Non-Randomized, Limited-Use Evaluation of the ENTact Septal Staple System for Tissue Approximation During Septoplasties

The purpose of this research study is to learn more about the ENTact™ Septal Staple System device performance and to collect information to support its premarket application.

Study Overview

Status

Completed

Conditions

Detailed Description

The ENTact™ Staple System is a device that inserts a small staple or tack to hold mucosa (moist tissues) in place instead of using stitches. The staple gradually dissolves and does not need to be removed. This clinical study will evaluate:

  • surgical performance of the ENTact Septal Staple System
  • one week post op clinical evaluation of gross tissue appearance at implantation site(s)
  • ENTact™ Septal Staple functionality based on maintained coaptation

Study Type

Observational

Enrollment (Actual)

25

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Ohio
      • Cincinnati, Ohio, United States, 45220
        • Good Samaritan Hospital
    • Texas
      • Bryan, Texas, United States, 77802
        • Park Hudson Surgery Center
      • San Antonio, Texas, United States, 78258
        • Physician's Ambulatory Surgery Center IV

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult patients (ages 18-65) with clinically significant nasal septum deviation.

Description

Inclusion Criteria:

  • Adult patients, between the ages of 18 and 65 years, with a clinically significant deviation of the nasal septum
  • Patient is able to provide a signed informed consent form
  • Patient will agree to comply with all study related procedures
  • Patient is not pregnant at this time. If patient is of child-bearing age and capable of bearing children, a pre-operative pregnancy test confirmation is required to show that patient is not pregnant on the day of surgery
  • Patient does not plan on becoming pregnant and is not breast feeding during the course of the study

Exclusion Criteria:

  • Patients who do not meet the inclusion criteria
  • Patients who have had previous septoplasty
  • Patients with uncontrolled diabetes
  • Presence of infection at the site
  • Smokers and severe drug and alcohol abusers
  • Patients with autoimmune disease deemed clinically significant by Principal Investigator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Surgical
Adult population (ages 18-65) with clinically significant nasal septum deviation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Coaptation (Tissue Approximation)
Time Frame: One week post surgery
Complete tissue approximation at one week.
One week post surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tissue Reaction to Implant
Time Frame: One week post surgery
None - no edema, erythema or purulence around the area of the staples Mild - slight erythema and/or edema in the region of one or more staple, limited to not greater than 2 mm from the staple Moderate - erythema and/or edema in the region of one or more staples, greater than 2 mm extension from the staples Severe - Generalized edema and/or erythema of the septum, or purulence and/or granulation tissue involved in one or more staples.
One week post surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

ENTrigue Surgical, Inc.

Investigators

  • Study Director: Gabriele G Niederauer, Ph.D., ENTrigue Surgical, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2008

Primary Completion (Actual)

February 1, 2009

Study Completion (Actual)

February 1, 2009

Study Registration Dates

First Submitted

August 21, 2008

First Submitted That Met QC Criteria

August 22, 2008

First Posted (Estimate)

August 25, 2008

Study Record Updates

Last Update Posted (Estimate)

August 25, 2009

Last Update Submitted That Met QC Criteria

August 20, 2009

Last Verified

August 1, 2009

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CSA 2008-01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nasal Septum

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe